0 references
The Germline HSD3B1 Variant Is Associated With Response to Androgen Deprivation Therapy and Abiraterone but not With Response to Enzalutamide in Chinese Prostate Cancer Patients
The Prostate2025Vol. 86(3), pp. 329–337
Ruofan Shi, Qijun Du, Chi Yao, Da Huang, Xiaohao Ruan, A. Lam, Kuen Chan, Tsun Tsun Stacia Chun, Yongqiu Wu, T.Y. Kam, Sk Subidh Ali, Dan-feng Xu, Rong Na
Abstract
The HSD3B1 germline variant (1245C) is linked to earlier ADT failure and diminished efficacy of abiraterone but does not affect enzalutamide in the treatment of PCa patients. These findings underscore its potential as a biomarker to guide personalized treatment in PCa.